Louise Dickinson1, Hashim U Ahmed2, Richard G Hindley3, Neil McCartan4, Alex Freeman5, Clare Allen6, Mark Emberton2, Alex P Kirkham6. 1. Division of Surgery and Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: ldickinson@doctors.org.uk. 2. Division of Surgery and Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK. 3. Department of Urology, Basingstoke Hospital, Hampshire Hospitals NHS Foundation Trust, Hampshire, UK. 4. Division of Surgery and Interventional Sciences, University College London, London, UK. 5. Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK. 6. Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Abstract
INTRODUCTION: Focal therapy for localized prostate cancer has the potential for oncological control without the side effects of radical therapies. However, there is currently no validated method for monitoring treatment success. We assessed the diagnostic performance of prostate-specific antigen (PSA) parameters and MRI compared to histological outcomes following focal therapy. PATIENTS AND METHODS: Patients from 3 Ethics Review Board approved prospective studies of focal high intensity-focused ultrasound (HIFU) (Sonablate 500) for localized prostate cancer (T1c-T3a, Gleason grade≤4+3, and PSA≤20). Post-HIFU PSA nadir, 6-month PSA, PSA density, and early (<3wk) and late (6mo) MRI (T2-weighted, dynamic contrast-enhanced±diffusion-weighted) was assessed for predictive accuracy of cancer on postoperative biopsy, using receiver operating characteristic (ROC) analysis and sensitivity, specificity, and positive and negative predictive estimates. ROC areas for MRI and PSA were compared. Calculations for statistical significance (P≤0.05) were obtained in a subset of patients comparing area under ROC for 6-month MRI and PSA criteria, across 4 different histological definitions of disease significance. RESULTS: Of 118 men, 111 underwent at least 1 postoperative biopsy (median 6 cores), with an overall positive biopsy rate of 37% (41/118), over a mean follow-up period of 716 days post-HIFU. Areas under ROC for early and late MRI were (depending on definition of significant disease) 0.65 to 0.76 and 0.77 to 0.85, respectively, with sensitivity, specificity, and negative predictive values of 68% to 91%, 52% to 55%, and 85% to 98% (early MRI), and 63% to 80%, 67% to 73%, and 86% to 97% (late MRI). The area under the ROC curve was statistically significantly higher for late MRI than 6 months and nadir PSA for residual disease >3mm or any Gleason 4 tumor. CONCLUSIONS: Early and late MRI performed better than PSA measurements in the detection of residual tumor after focal therapy. Crown
INTRODUCTION: Focal therapy for localized prostate cancer has the potential for oncological control without the side effects of radical therapies. However, there is currently no validated method for monitoring treatment success. We assessed the diagnostic performance of prostate-specific antigen (PSA) parameters and MRI compared to histological outcomes following focal therapy. PATIENTS AND METHODS: Patients from 3 Ethics Review Board approved prospective studies of focal high intensity-focused ultrasound (HIFU) (Sonablate 500) for localized prostate cancer (T1c-T3a, Gleason grade≤4+3, and PSA≤20). Post-HIFU PSA nadir, 6-month PSA, PSA density, and early (<3wk) and late (6mo) MRI (T2-weighted, dynamic contrast-enhanced±diffusion-weighted) was assessed for predictive accuracy of cancer on postoperative biopsy, using receiver operating characteristic (ROC) analysis and sensitivity, specificity, and positive and negative predictive estimates. ROC areas for MRI and PSA were compared. Calculations for statistical significance (P≤0.05) were obtained in a subset of patients comparing area under ROC for 6-month MRI and PSA criteria, across 4 different histological definitions of disease significance. RESULTS: Of 118 men, 111 underwent at least 1 postoperative biopsy (median 6 cores), with an overall positive biopsy rate of 37% (41/118), over a mean follow-up period of 716 days post-HIFU. Areas under ROC for early and late MRI were (depending on definition of significant disease) 0.65 to 0.76 and 0.77 to 0.85, respectively, with sensitivity, specificity, and negative predictive values of 68% to 91%, 52% to 55%, and 85% to 98% (early MRI), and 63% to 80%, 67% to 73%, and 86% to 97% (late MRI). The area under the ROC curve was statistically significantly higher for late MRI than 6 months and nadir PSA for residual disease >3mm or any Gleason 4 tumor. CONCLUSIONS: Early and late MRI performed better than PSA measurements in the detection of residual tumor after focal therapy. Crown
Authors: Ely R Felker; Steven S Raman; David S K Lu; Mitch Tuttle; Daniel J Margolis; Fuad F ElKhoury; James Sayre; Leonard S Marks Journal: AJR Am J Roentgenol Date: 2019-07-30 Impact factor: 3.959
Authors: Philipp M Huber; Naveed Afzal; Manit Arya; Silvan Boxler; Tim Dudderidge; Mark Emberton; Stephanie Guillaumier; Richard G Hindley; Feargus Hosking-Jervis; Lucas Leemann; Henry Lewi; Neil McCartan; Caroline M Moore; Raj Nigam; Chris Odgen; Raj Persad; Jaspal Virdi; Mathias Winkler; Hashim U Ahmed Journal: World J Urol Date: 2020-07-07 Impact factor: 4.226
Authors: Antony Pellegrino; Giuseppe O Cirulli; Elio Mazzone; Francesco Barletta; Simone Scuderi; Mario de Angelis; Giuseppe Rosiello; Giorgio Gandaglia; Francesco Montorsi; Alberto Briganti; Armando Stabile Journal: Ann Transl Med Date: 2022-07
Authors: Mark Paxton; Eitan Barbalat; Nathan Perlis; Ravi J Menezes; Mark Gertner; David Dragas; Masoom A Haider; Antonio Finelli; John Trachtenberg; Sangeet Ghai Journal: Br J Radiol Date: 2021-07-29 Impact factor: 3.039
Authors: Stephanie Guillaumier; Max Peters; Manit Arya; Naveed Afzal; Susan Charman; Tim Dudderidge; Feargus Hosking-Jervis; Richard G Hindley; Henry Lewi; Neil McCartan; Caroline M Moore; Raj Nigam; Chris Ogden; Raj Persad; Karishma Shah; Jan van der Meulen; Jaspal Virdi; Mathias Winkler; Mark Emberton; Hashim U Ahmed Journal: Eur Urol Date: 2018-06-28 Impact factor: 20.096
Authors: Arnas Bakavicius; Giancarlo Marra; Petr Macek; Cary Robertson; Andre L Abreu; Arvin K George; Bernard Malavaud; Patrick Coloby; Pascal Rischmann; Marco Moschini; Ardeshir R Rastinehad; Abhinav Sidana; Armando Stabile; Rafael Tourinho-Barbosa; Jean de la Rosette; Hashim Ahmed; Thomas Polascik; Xavier Cathelineau; Rafael Sanchez-Salas Journal: Int Braz J Urol Date: 2022 Mar-Apr Impact factor: 1.541
Authors: Sharon L Giles; Jessica M Winfield; David J Collins; Ian Rivens; John Civale; Gail R Ter Haar; Nandita M deSouza Journal: Eur Radiol Exp Date: 2018-05-10